Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560936 | 0.94 | TSHR (0.45) | L3MBTL1TDP1TSHRNAAAMEN1 | |
| SCHEMBL5087201 | 0.86 | PKM (0.47) | L3MBTL1TDP1TSHRMEN1HTT | |
| SCHEMBL5087200 | 0.86 | PKM (0.47) | L3MBTL1TDP1TSHRMEN1HTT | |
| SCHEMBL10614250 | 0.82 | TSHR (0.61) | TSHRCYP3A4 | |
| SCHEMBL32667934 | 0.81 | SRC (0.48) | L3MBTL1TDP1PKM | |
| SCHEMBL343402 | 0.80 | SRC (0.52) | L3MBTL1TDP1MEN1HTTKMT2A | |
| SCHEMBL381492 | 0.79 | TSHR (0.57) | L3MBTL1TDP1TSHRMEN1HTT | |
| SCHEMBL28639421 | 0.78 | ALDH1A1 (0.44) | L3MBTL1TDP1MEN1KMT2APKM | |
| SCHEMBL9818167 | 0.77 | SRC (0.48) | L3MBTL1TDP1PKM | |
| SCHEMBL26189830 | 0.77 | TSHR (0.67) | L3MBTL1TDP1TSHRNAAAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | L3MBTL1 3648/4885TDP1 4687/4885TSHR 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.